Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
551 studies found for:    PAH
Show Display Options
Rank Status Study
21 Enrolling by invitation Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Inhaled Nitric Oxide
22 Active, not recruiting Auto-immunity and Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   HIV Infection;   Congenital Heart Defect;   Systemic Sclerosis;   Connective Tissue Disease
Interventions: Procedure: skin biopsy;   Other: Blood Sample
23 Completed
Has Results
Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sitaxentan sodium
24 Completed Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Sildenafil;   Drug: Sugar Pill
25 Recruiting Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: iNO 15 mcg/kg IBW/hr;   Drug: iNO 75 mcg/kg IBW/hr;   Drug: Placebo Dose setting of 15 mcg/kg IBW/hr;   Drug: Placebo Dose setting of 75 mcg/kg IBW/hr
26 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: Model 10642 Implantable Intravascular Catheter
27 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
28 Completed An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
29 Recruiting National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention:
30 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
31 Completed A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost sodium modified release
32 Completed Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sorafenib
33 Not yet recruiting Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Fulvestrant
34 Recruiting Effects of Oral Sildenafil on Mortality in Adults With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
35 Unknown  The Expression and Significance of MiRNA
Condition: Pulmonary Arterial Hypertension
Intervention:
36 Active, not recruiting Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
37 Recruiting Carvedilol PAH A Pilot Study of Efficacy and Safety
Conditions: Pulmonary Hypertension;   Cardiac MRI <40
Intervention: Drug: Carvedilol
38 Terminated A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
39 Terminated A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
40 Completed Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis
Intervention: Drug: Inhaled Nitric Oxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years